ESR1 and Hepatic fibrosis: By treating HSCs with ERα and ERβ blockers and establishing αERKO and βERKO knockout liver fibrosis mouse models, we found that the experimental results obtained from mouse and cellular model groups were not significantly different from those obtained from the THC intervention group and the βERKO mouse group, while there were significant differences between the MPP intervention group, the αERKO mouse group and the control group.